Follow in Biological Technology

Corn Growers Reminded to Follow Refuge Requirements as Spring Planting Nears

National Corn Growers Association reminds U.S. Bt corn growers that the development of an Insect Resistance Management plan is an essential and required part of their planning process. St. Louis, MO (PRWEB) February 20, 2009 -- As the 2009 planting season approaches, ...

Graphene pioneers follow in Nobel footsteps

Two physicists from The University of Manchester who discovered the world's thinnest material have scooped a major award for their work. Professor Andre Geim FRS and Dr Kostya Noveselov of the Centre of Mesoscience and Nanotechnology have been awarded the prestigious Europhysics Prize for disco...

Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics

RICHMOND, Va., Feb. 11 /PRNewswire-FirstCall/ -- A report released today, commissioned by Insmed Inc. (Nasdaq: INSM ), identifies potential cost savings of approximately $378 billion over the next 20 years from making follow on biologics (FOBs) available in the U.S. The econometric study by...

Senate Passes an Investment Capital Package; the Assembly Should Follow Suit

MADISON State Sen. Ted Kanavas was still beaming on Saturday, a day after the Legislatures upper house passed bills that could close Wisconsins venture capital gap and build a stronger in-state network for entrepreneurs Not that we havent dealt with some pretty big issues this fall, but this is...

Lead, follow or get out of the way

What happens in your community when power stands still? A. Things stall; nothing gets done. B. Fingers begin to wag; its always someone elses fault. C. Young professionals shake their heads and start their own initiative. If you answered "C," you might be living in a Next Generati...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... Actimmune(R) is a registered trademark of InterMune, Inc. Pegasys(R) and Copegus(R) are registered trademarks of Roche. Financial tables follow InterMune, Inc. PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...clitaxel-eluting peripheral stent were free from reintervention at two-year follow up. The ZILVER PTX Registry study, involving 792 patients globally, is asse...tact stents (less than 1 percent stent fracture rates observed) with a mean follow up of 2.4 years in the challenging superior femoral artery and popliteal ar...

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

...grateful to sanofi-aventis for advancing NIH-sponsored clinical research with this generous donation and hope that other pharmaceutical companies will follow its lead." "We are proud to support the ability of the NIH to pursue new and cutting-edge research by freeing up much needed resources," said ...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

...m . The web broadcast of the conference call will be available for replay through Wednesday, August 19, 2009. To access the conference call, follow these instructions: Dial: (866) 831-6270 (U.S.); (617) 213-8858 (international) Passcode: 25099763 (Howard Robin is the host) An audi...

Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call

...e hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (866) 206-5917 (International: 1 (703) 639-1106. A live audio w...

First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009

...ting Beike to life in China to returning home. This U.K. rally will be the association's first event held outside of the United States and will follow in the footsteps of previous events by creating a community where stem cell patients have the opportunity to share their experiences with prospective ...

World Renowned Scientists Gather to Share Latest Information on Answer to Wildlife Reproductive Fertility Control

...he past seven years. "The City of Flagstaff, through its incubator program at the Northern Arizona Center for Emerging Technologies has allowed us to follow the Arizona Biotechnology Road Map from the Arizona universities to technology transfer and onto the road to commercialization" said Everett Hale, CEO...

SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia

...l, including efficacy, safety and tolerability data, will be submitted for presentation at a medical meeting at a later date. These results follow those of a previously reported clinical trial in this patient population using the same study design and protocol in which both asenapine and olanzapi...

Varian, Inc. to Webcast Conference Call on Third Quarter Fiscal Year 2009 Financial Results

...T) on Wednesday, July 29, 2009. A live webcast (in listen-only mode) of its investor conference call to review those quarterly results is scheduled to follow at 2:00 p.m. PT that same day. That live webcast can be accessed from Varian, Inc.'s Web site at www.varianinc.com . Go to www.varianinc...

Dow AgroSciences, Monsanto Complete U.S. and Canadian Regulatory Authorizations for SmartStax Corn; Plans Set to Launch Seed Platform on 3 Million- to 4 Million-Plus Acres

...s. Monsanto will manage the licensing process for itself and as an agent for Dow AgroSciences. Consistent with both companies' commitment to follow the Biotechnology Industry Organization's (BIO) Product Launch Stewardship Policy, Dow AgroSciences and Monsanto are also working with the regulatory ...

Essilor : First Half 2009 Revenue

...conference will be available for later listening at: http://hosting.3sens.com/Essilor/20090717-1F5418C3/fr/ A conference call in English will follow at 10:00 a.m. CEST. The number to dial is: + 44-20-7138-0843 The conference will be available for later listening at: http://hosting.3sens...

China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results

...eflect events or circumstances after the date of this document, except as required by applicable law. - FINANCIAL TABLES follow - CHINA-BIOTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Amount...

GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients

... White House already has the FDA working on creating a pathway and it has firmly stated that seven years of exclusivity is a good compromise. We must follow the course of the White House and Chairman Waxman and ensure that patients can truly access lifesaving biogeneric medicines in a timely manner. ...

Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia

...fusion into a major artery. Prof. K. S. Vijayaragavan presented interim results on the first thirty patients treated with at least twelve weeks follow up at the Cardiovascular Research Foundation meeting on January 15, 2009 in New York City. He showed a limb salvage rate of 87.5% and significant im...

Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website

...ent Information" available at http://www.pinksheets.com/content/doc/ps/Disclosure/Guidelines/2.pdf . The guidelines are intended to substantially follow the reporting requirements of registrants under Section 12 of the Securities Exchange Act administered by the SEC, although the requirements are volun...

New Report Just Published: World Endoscopy Systems Market Report

...idoscopy II-28 Choledoscopy II-28 Esophagogastroduodenoscopy / Gastroscopy / Upper Endoscopy II-28 Small Bowel Radiograph II-28 Barium follow Through Technique II-28 Enteroclysis II-28 Tagged Red Blood Cells II-28 Angiography II-28 Virtual Endoscopy II-28 Arthroscopy II-2...

CEL-SCI Corporation Releases Letter to Shareholders

... 2. Study too small: Our study will enroll about 800 patients, a very sizeable number. 3. Clinical endpoint not relevant: We follow overall survival of the patients, the gold standard. The Clinical endpoint cannot be more relevant. 4. Change in treatment protocol bet...

Celebrities to Gather to Support the Ninth Annual Starkey Hearing Foundation 'So the World May Hear' Awards Gala

... hearing instruments to those in need around the world. Become a Starkey Hearing Foundation fan by visiting Facebook at http://www.facebook.com , follow Starkey Hearing Foundation on Twitter at http://twitter.com/starkeyhearing , or visit us at http://www.starkeyhearingfoundation.org . ...

Cephalon Quarterly Conference Call Invitation

...l live by logging on to the company's website at www.cephalon.com and clicking on the "Investors" tab then "Webcast." Please click on the link and follow the prompts for registration and access. If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be availa...

febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment

...r the mouse genome, febit complements its offering for up-to-date sequence analyses in the field of mammalian research. Biochips for other models will follow as soon as the appropriate sequence analyses are completed. febit biochips are available for analysis at the Geniom RT Analyzer or as a full service f...

Qforma Appoints Four Executives in Sales and Field Operations

...Operations to Vice President, Sales and Services; and Rod Anaforian and Kim Foster join Qforma as Directors, Field Operations. These appointments follow a series of important milestones for Qforma in 2009, highlighted by the launch in May of the "Most Influential Doctors" (MID) database, a new quarterl...

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

...include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefi...

Matthew Lehman of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar

... Companies should deliver reasoned proposals and obtain yes/no answers." Although it should be simple to secure agreement with the FDA and then follow through on a development plan, competing interests and operational realities can take programs off track. Management and shareholders need to be awar...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

...overall survival in the elacytarabine study was an impressive three times that of the historical control patients (5.5 months vs. 1.5 months). Further follow up on survival is ongoing. In addition, 9 patients responded to elacytarabine with a complete remission or complete remission without full reco...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

...f this week. Therefore, data analysis and reporting will be brought forward from the scheduled fourth quarter into the third quarter of 2009, and will follow the disclosure of results from the first double-blind placebo controlled efficacy study (study 033). BPH is a benign enlargement of the prostate, affe...

Lumbar Matrix(TM) Scan From SpineMatrix(R) Revolutionizes the Diagnosis of Low Back Pain

...ng to ineffective treatment and billions of dollars spent in unnecessary healthcare costs. Additionally, invasive procedures, including surgery, may follow misdiagnosed lower back pain, further elevating healthcare spending. Since 1997, U.S. spending on diagnosis and treatment of spinal disorders increas...

Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

...lease see http://www.slideshare.net/accesspharma/mugard-for-oral-mucositis ). For latest information on the Company and its products, please follow Access on Facebook and Twitter . Access has announced that MuGard(TM) was launched in Germany, Italy, UK, Greece and the Nordic countries...

Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants

...s for cultivation in the United States and Canada, and for import to Mexico, the European Union and Colombia. Submissions in other import markets will follow in the months to come. In any given year, 10 million to 13 million acres of farmland planted to corn in the United States may be affected by at l...

Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use

...nually. Immunotherapeutic interventions using live-cell DC vaccines may potentially be effective in CRC patients. To date, the inability to accurately follow the location of the cells after transfer to the patient is one of the critical bottlenecks in the development and delivery of cancer immunotherapies. ...

Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis

...s and pharmacodynamics of a single dose of DR Cysteamine in patients. Data from the study are expected in the third quarter of 2009. Raptor plans to follow the Phase 2b clinical study with a pivotal, Phase 3 clinical study in cystinosis patients anticipated to commence in the fourth quarter of 2009. ...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

...include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefi...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

...include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefi...

Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists

...y that enables testing on fixed tissue. Launch of the first molecular diagnostic product was announced in December 2008. A number of new products will follow in the years ahead. Using the LNA(TM) technology is what has allowed Exiqon to establish a position for itself as one of the market's leading provider...

DHS Begins Test of Biometric Exit Procedures at Two U.S. Airports

...ting the United States by air within the next year. Non-U.S. citizens departing the United States from all other ports of entry will continue to follow current exit procedures, which require travelers to return their paper Form I-94 (Arrival-Departure Record) or Form I-94W (for Visa Waiver Program tra...

Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors

...fects of CNTF observed in these two Phase 2 RP studies," commented Ted Danse, President and Chief Executive Officer of Neurotech. "We will continue to follow the patients in these studies and plan to discuss the results and the clinical development path with the Food and Drug Administration (FDA)," added Mr...